HKG:2496

Update: Wuhan YZY Biopharma, Sino Biopharm Unit's Application for Ascites Drug Accepted in China

(Updated to include Wuhan YZY Biopharma, the drug's primary developer)A new drug application for Wuhan YZY Biopharma's (HKG:2496) M701, a drug co-developed by a unit of Sino Biopharmaceutical (HKG:1177), was accepted by China's National Medical Products Administration.The drug was developed for the treatment of malignant ascites caused by advanced epithelial malignancies, according to two separate filings posted with the Hong Kong bourse Thursday.Chia Tai Tianqing Pharmaceutical Group, Sino Biopharmaceutical's unit had, in August 2024, obtained an exclusive sub-licensable license to register, develop, produce, and commercialize the drug in Mainland China.